Eloctate (efmoroctocog alfa) for hemophilia
Eloctate (efmoroctocog alfa) is an extended half-life therapy that's approved to prevent and treat bleeds, including those occurring during surgery, in adults and children with hemophilia A.
Search results for:
December 1, 2023
by Susie Strachan
Hemophilia A vs. B: Differences and similarities
While hemophilia A and hemophilia B are both bleeding disorders characterized by deficiencies in blood clotting factors, there are differences in one type versus the other, particularly in the specific genetic mutations that cause the disease, and in some of the treatment methods.
November 30, 2023
by Marisa Wexler, MS
BeneFIX (nonacog alfa) for hemophilia
BeneFIX (nonacog alfa) is a recombinant, or man-made, clotting factor therapy approved to prevent and treat bleeding episodes, including those occurring during surgery, in adults and children with hemophilia B.
FDA awards support Sernova’s work into Cell Pouch for hemophilia A
The U.S. Food and Drug Administration (FDA) has given orphan drug and rare pediatric disease designations to Sernova’s experimental and cell-based hemophilia A treatment program using the Cell Pouch System, the company’s novel medical device. Orphan drug status is awarded to therapies aiming to treat…
Why my husband with hemophilia can be hard on himself
My husband, Jared, is a diligent worker and constant high achiever. An honor student in school, he has since excelled in various fields. From running a business to trying his hand at voice acting and cooking, he’s a jack of all trades in the most complete form of the…
A reminder about preparing my son with hemophilia for life on his own
Raising two sons with a bleeding disorder has given me hundreds of stories. Many of them lead to happiness and gratitude. Others are filled with pain and suffering. They are all a part of me in a way I never imagined they would be. The nice thing about having so…
November 22, 2023
by Margarida Maia, PhD
Obizur (susoctocog alfa) for hemophilia
Last updated Nov. 21, 2023, by Margarida Maia, PhD ✅ Fact-checked by Joana Carvalho, PhD What is Obizur for hemophilia? Obizur (susoctocog alfa) is a recombinant, or man-made, antihemophilic factor therapy approved for the on-demand treatment of bleeding episodes in adults with acquired…
My husband’s hemophilia helped him sense his life purpose early
One ordinary evening, while a dear cousin and I relaxed in my living room, we delved into a profound conversation about purpose. We pondered why some people who struggle with mental health would cling to altruistic pursuits despite financial challenges they may have, especially since those challenges could create more…
Rethinking the classification of hemophilia to reflect its complexity
In the realm of hemophilia, I believe the current classification system oversimplifies a far more intricate reality. Severe, moderate, and mild hemophilia are classifications based on the amount of clotting factor present in a person’s blood. Hemophilia is a genetic disorder that impairs the blood’s ability…
Gene therapy for hemophilia A reduces bleeding in clinical trial
GS1191, a gene therapy in the pipeline of Gritgen Therapeutics, increased factor VIII (FVIII) activity in the blood of people with hemophilia AÂ taking part in a small clinical trial in China, resulting in fewer bleeding episodes. The fully enrolled investigator-initiated trial (ChiCTR2300073179) is testing the safety and…